Compare Alnylam Pharmaceuticals, Inc. (ALNY) vs Bristol-Myers Squibb Co (BMY) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Alnylam Pharmaceuticals, Inc. vs Bristol-Myers Squibb Co — how do they compare? Alnylam Pharmaceuticals, Inc. trades at $299.01 (market cap $39.89B), while Bristol-Myers Squibb Co trades at $57.8 (market cap $117.58B). The key difference: Bristol-Myers Squibb Co is far larger — about 2.9× Alnylam Pharmaceuticals, Inc.'s market cap, and Bristol-Myers Squibb Co pays a 4.38% dividend while Alnylam Pharmaceuticals, Inc. pays none. Which is the better fit depends on your goals.
| ALNY | BMY | |
|---|---|---|
Market Cap | $39.89B | $117.58B |
Sector | Health | Health |
52-Week High | $491.22 | $62.37 |
52-Week Low | $278.09 | $42.60 |
Enterprise Value | $38.15B | $153.52B |
Dividend Yield | — | 4.38% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
ALNY trades at $298.76, down 4.49% today, but maintains a bullish technical outlook with strong support at $290. The company reported robust revenue growth to $3.71 billion in 2025, turning profitable with net income of $313.75 million. Analyst consensus is strongly bullish with a $429.50 price target, supported by positive news on drug pipelines and AI partnerships.
Outlook remains positive driven by expanding product portfolio and strategic collaborations, though risks include clinical trial outcomes and high valuation multiples. Earnings beats in recent quarters reinforce growth trajectory, but dependence on key drug Amvuttra and competitive pressures warrant monitoring for sustained shareholder value.
Bristol Myers Squibb (BMY) trades at $57.58, down 0.62% on the day, with a bullish technical signal from moving averages. The company demonstrates strong profitability with a 70.46% gross margin and 15.01% net income margin, though it faces a patent cliff risk. Recent earnings have consistently beaten expectations, with Q1 2026 EPS of $1.58 surpassing the $1.42 estimate. Analyst consensus shows a mixed but leaning positive view with 46% buy ratings and a $60 price target.
BMY offers value with a reasonable P/E of 16.13 and attractive 4.3% dividend yield, supported by 36 years of uninterrupted payments. However, investors must weigh the patent expiration headwinds against the company's growth portfolio, which now represents 54.1% of revenues. The stock presents a balanced opportunity for income-focused investors with moderate growth potential amid ongoing business transformation.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Alnylam Pharmaceuticals, Inc.
Alnylam Pharmaceuticals is a leader in the study of RNA interference (RNAi) therapeutics. RNAi is a naturally occurring biological pathway within cells for sequence-specific silencing and regulation of gene expression. Alnylam has five drugs on the market: Onpattro and Amvuttra for hATTR amyloidosis, Givlaari for acute hepatic porphyria, Oxlumo for primary hyperoxaluria type 1, and Leqvio for hypercholesterolemia.
Read more on ALNY →About Bristol-Myers Squibb Co
Bristol-Myers Squibb discovers, develops, and markets drugs for various therapeutic areas, such as cardiovascular, cancer, and immune disorders. A key focus for Bristol is immuno-oncology, where the firm is a leader in drug development. Unlike some of its more diversified peers, Bristol has exited several nonpharmaceutical businesses to focus on branded specialty drugs, which tend to support strong pricing power.
Read more on BMY →
